Bevacizumab in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for first-line and maintenance treatment of metastatic colorectal cancer

References

• Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.
   PubMed Web of Science ®Google Scholar
• Edwards BK, Ward E, Kohler BA, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116:544–573.
   PubMed Web of Science ®Google Scholar
• Bosetti C, Levi F, Rosato V, et al. Recent trends in colorectal cancer mortality in Europe. Int J Cancer. 2011;129:180–191.
   PubMed Web of Science ®Google Scholar
• Gill S, Blackstock AW, Goldberg RM. Colorectal cancer. Mayo Clin Proc. 2007;82:114–129.
   PubMed Web of Science ®Google Scholar
• Scheithauer W, Rosen H, Kornek GV, et al. Randomised comparison of combination chemotherapy plus supportive care alone in patients with metastatic colorectal cancer. BMJ. 1993;306:752–755.
   PubMed Web of Science ®Google Scholar
• Bekaii-Saab T, Wu C. Seeing the forest through the trees: a systematic review of the safety and efficacy of combination chemotherapies used in the treatment of colorectal cancer. Crit Rev Oncol Hematol. 2014;91:9–34.
   PubMed Web of Science ®Google Scholar
• Jackson AL, Zhou B, Kim WY. HIF, hypoxia and the role of angiogenesis in non-small cell lung cancer. Expert Opin Ther Targets. 2010;14:1047–1057.
   PubMed Web of Science ®Google Scholar
• Edelman MJ, Hodgson L, Wang X, et al. Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer. Cancer and Leukemia Group B 150304. J Thorac Oncol. 2011;6:1902–1906.
   PubMed Web of Science ®Google Scholar
• Folkman J. Seminars in Medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med. 1995;333:1757–1763.
   PubMed Web of Science ®Google Scholar
• Woodhouse EC, Chuaqui RF, Liotta LA. General mechanisms of metastasis. Cancer. 1997;80:1529–1537.
   PubMed Web of Science ®Google Scholar
• Rosen LS. Clinical experience with angiogenesis signaling inhibitors: focus on vascular endothelial growth factor (VEGF) blockers. Cancer Control. 2002;9:36–44.
   PubMedGoogle Scholar
• Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst. 1990;82:4–6.
   PubMed Web of Science ®Google Scholar
• Folkman J, Klagsbrun M. Angiogenic factors. Science. 1987;235:442–447.
   PubMed Web of Science ®Google Scholar
• Choi JH, Kim HC, Hy L, et al. Vascular endothelial growth factor in the serum of patients with non-small cell lung cancer: correlation with platelet and leucocyte counts. Lung Cancer. 2001;33:171–179.
   PubMed Web of Science ®Google Scholar
• Dvorak HF, Brown LF, Detmar M, et al. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol. 1995;146:1029–1039.
   PubMed Web of Science ®Google Scholar
• Roberts WG, Palade GE. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J Cell Sci. 1995;108:2369–2379.
   PubMed Web of Science ®Google Scholar
• Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2005;23:1011–1027.
   PubMed Web of Science ®Google Scholar
• Nagy JA, Vasile E, Feng D, et al. Vascular permeability factor/vascular endothelial growth factor induces lymphangiogensis as well as angiogenesis. J Exp Med. 2002;196:1497–1506.
   PubMed Web of Science ®Google Scholar
• Li J, Saif MW. Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers. Biologics. 2009;3:429–441.
   PubMedGoogle Scholar
• Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med. 1999;5:1359–1364.
   PubMed Web of Science ®Google Scholar
• Ignoffo RJ. Overview of bevacizumab: a new cancer therapeutic strategy targeting vascular endothelial growth factor. Am J Health Syst Pharm. 2004;61:S21–26.
   PubMed Web of Science ®Google Scholar
• Chase JL. Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer. Pharmacotherapy. 2008;23S–30S.
   Google Scholar
• Kim KJ, Li B, Houck K, et al. The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors. 1992;7:53–64.
   PubMedGoogle Scholar
• Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:303–312.
   PubMed Web of Science ®Google Scholar
• Ellis LM. Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer. Semin Oncol. 2006;33:S1–7.
   PubMed Web of Science ®Google Scholar
• Iqbal S, Lenz HJ. Integration of novel agents in the treatment of colorectal cancer. Cancer Chemother Pharmacol. 2004;54:S32–39.
   PubMed Web of Science ®Google Scholar
• Von Baumgarten L, Brucker D, Tirniceru A, et al. Bevacizumab has differential and dose-dependent effects on glioma blood vessels and tumor cells. Clin Cancer Res. 2011;17:6192–6205.
   PubMed Web of Science ®Google Scholar
• Welch S, Spithoff K, Rumble RB, et al. Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review. Ann Oncol. 2010;21:1152–1162.
   PubMed Web of Science ®Google Scholar
• Mohile SG, Hardt M, Tew W, et al. Toxicity of bevacizumab in combination with chemotherapy in older patients. Oncologist. 2013;18:408–414.
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335–2342. The results of this study led to the FDA approval of bevacizumab for use in treatment of advanced colorectal cancer.
   PubMed Web of Science ®Google Scholar
• Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional bolus or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C study. J Clin Oncol. 2007;25:4779–4786.
   PubMed Web of Science ®Google Scholar
• Fuchs CS, Marschall J, Barrueco J. Randomized, controlled trial of irinotecan plus infusional bolus or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol. 2008;26:689–690.
   PubMed Web of Science ®Google Scholar
• Sobrero A, Ackland S, Clarke S, et al. Phase IV study of bevacizumab in combination with infusional fluorouracil, leucovorin and irinotecan (FOLFIRI) in first-line metastatic colorectal cancer. Oncology. 2009;77:113–119.
   PubMed Web of Science ®Google Scholar
• Heinemann V, Von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomized, open-label, phase 3 trial. Lancet Oncol. 2014;15:1067–1075.
   Web of Science ®Google Scholar
• Saltz LB, Clarke S, Diaz-Rubio E, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26:2013–2019.
   PubMed Web of Science ®Google Scholar
• Hochster HS, Hart LL, Ramanathan RK, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE study. J Clin Oncol. 2008;26:3523–3529.
   PubMed Web of Science ®Google Scholar
• Schmoll HJ, Cunningham D, Sobrero A, et al. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III). J Clin Oncol. 2012;30:3588–3595.
   PubMed Web of Science ®Google Scholar
• Hochster HS, Grothey A, Shpilsky A et al. Effect of intravenous (IV) calcium and magnesium (Ca/Mg) versus placebo on response to FOLFOX+bevacizumab (BEV) in the CONcePT trial. Gastrointestinal Cancers Symp. 2008;23: Abstract 280.
   Google Scholar
• Stintzing S, Fischer Von Weikersthal F, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS mutated tumours in the randomized German AIO study KRK-0306. Ann Oncol. 2012;23:1693–1699.
   PubMed Web of Science ®Google Scholar
• Schwartzberg LS, Rivera F, Karthaus M, et al. PEAK: a randomized multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol. 2014;32:2240–2247.
   PubMed Web of Science ®Google Scholar
• Venook AP, Niedzwiecki D, Lenz HJ, et al. CALGB/SWOG 80405: phase III trial of irinotecan/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetixumab (CET) for patients with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). Proc Am Soc Clin Oncol. 2014;32: LBA3 (abstr).
   Google Scholar
• Masi G, Loupakis F, Salvatore L, et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial. Lancet Oncol. 2010;11:845–852.
   PubMed Web of Science ®Google Scholar
• Loupakis F, Cremolinr C, Masi G, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med. 2014;371:1609–1618.
   PubMed Web of Science ®Google Scholar
• Gruenberger T, Bridgewater J, Chau I, et al. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomized phase II trial. Ann Oncol. 2015;26:702–708.
   PubMed Web of Science ®Google Scholar
• Diaz-Rubio E, Gomez-Espana A, Massuti B, et al. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. Oncologist. 2012;17:25–35.
   Google Scholar
• Rosati G, Avallone A, Aprile G, et al. XELOX and bevacizumab followed by single-agent bevacizumab as maintenance therapy as first-line treatment in elderly patients with advanced colorectal cancer: the boxe study. Cancer Chemother Pharmacol. 2013;71:257–264.
   PubMed Web of Science ®Google Scholar
• Johnsson A, Hagman H, Frodin JE, et al. A randomized phase III trial on maintenance treatment with bevacizumab alone or in combination with erlotinib after chemotherapy and bevacizumab in metastatic colorectal cancer: the Nordic ACT trial. Ann Oncol. 2013;24:2335–2341.
   PubMed Web of Science ®Google Scholar
• Koeberle D, Betticher DC, Von Moos R, et al. Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06). Ann Oncol. 2015;26:709–714.
   PubMed Web of Science ®Google Scholar
• Simkens LH, Van Tinteren H, May A, et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomized controlled trial of the Dutch Colorectal Cancer Group. Lancet. 2015;385:1843–1852.
   PubMed Web of Science ®Google Scholar
• Hegewisch-Becker S, Graeven U, Lerchenmuller CA, et al. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomized, non-inferiority, open-label, phase 3 trial. Lancet Oncol. 2015. DOI:10.1016/S1470-2045(15)00042-X. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Heidelberger C, Chaudhuri NK, Danneberg P, et al. Fluorinated pyrimidines, a new class of tumor-inhibitory compounds. Nature. 1957;179:663–666.
   PubMed Web of Science ®Google Scholar
• Ullman B, Lee M, Martin DW Jr, et al., Cytotoxicity of 5-fluoro-2-deoxyuridine: requirement for reduced folate cofactors and antagonism by methotrexate. Proc Natl Acad Sci USA. 1978;75:980–983.
   PubMed Web of Science ®Google Scholar
• Keyomarsi K, Moran RG. Folinic acid augmentation of the effects of fluoropyrimidines on murine and human leukemic cells. Cancer Res. 1986;46:5229–5235.
   PubMed Web of Science ®Google Scholar
• Radparvar S, Houghton PJ, Houghton JA. Effect of polyglutamylation of 5,10-methylenetetrahydrofolate on the binding of 5-fluoro-2-deoxyuridylate to thymidylate synthase purified from a human colon adenocarcinoma xenograft. Biochem Pharmacol. 1989;38:335–342.
   PubMed Web of Science ®Google Scholar
• Park JG, Collins JM, Gazdar AF, et al. Enhancement of fluorinated pyrimidine-induced cytotoxicity by leucovorin in human colorectal carcinoma cell lines. J Natl Cancer Inst. 1988;80:1560–1564.
   PubMed Web of Science ®Google Scholar
• Machover D, Schwarzenberg L, Goldschmidt E, et al. Treatment of advanced colorectal and gastric adenocarcinomas with 5-FU combined with high-dose folinic acid: a pilot study. Cancer Treat Rep. 1982;66:1803–1807.
   PubMedGoogle Scholar
• Madajewicz S, Petrelli N, Rustum YM, et al. Phase I-II trial of high-dose calcium leucovorin and 5-fluorouracil in advanced colorectal cancer. Cancer Res. 1984;44:4667–4669.
   PubMed Web of Science ®Google Scholar
• Petrelli N, Douglass HO Jr, Herrera L, et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group. J Clin Oncol. 1989;7:1419–1426.
   PubMed Web of Science ®Google Scholar
• Petrelli N, Herrera L, Rustum Y, et al. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol. 1987;5:1559–1565.
   PubMed Web of Science ®Google Scholar
• Thirion P, Michiels S, Pignon JP, et al. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol. 2004;22:3766–3775.
   PubMed Web of Science ®Google Scholar
• Gustavvson B, Carlsson G, Machover D, et al. A review of the evolution of systemic chemotherapy in the management of colorectal cancer. Clin Colorectal Cancer. 2015;14:1–10.
   PubMed Web of Science ®Google Scholar
• Goldberg RM. Advances in the treatment of metastatic colorectal cancer. Oncologist. 2005;10(Suppl 3):40–48.
   PubMed Web of Science ®Google Scholar
• Twelves C, Xeloda Colorectal Cancer Group. Capecitabine as first-line treatment in colorectal cancer. Pooled data from two large, phase III trials. Eur J Cancer. 2002;38(Suppl 2):15–20.
   PubMedGoogle Scholar
• Cassidy J, Twelves C, Van Cutsem E, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol. 2002;13;566–575.
   PubMed Web of Science ®Google Scholar
• Diaz-Rubio E, Sastre J, Zaniboni A, et al. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study. Ann Oncol. 1998;9:105–108.
   PubMed Web of Science ®Google Scholar
• Becouarn Y, Ychou M, Ducreux M, et al. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. J Clin Oncol. 1998;16:2739–2744.
   PubMed Web of Science ®Google Scholar
• Rougier P, Bugat R, Douillard JY, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naïve patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol. 1997;1:251–260.
   Google Scholar
• Firvida JL, Irigoyen A, Vazquez-Estevez S, et al. Phase II study of irinotecan as first-line chemotherapy for patients with advanced colorectal carcinoma. Cancer. 2001;91:704–711.
   PubMed Web of Science ®Google Scholar
• Zori Comba A, Blajman C, Richardet E, et al. A randomized phase II study of oxaliplatin alone versus oxaliplatin combined with 5-fluorouracil and folinic acid (Mayo Clinic regimen) in previously untreated metastatic colorectal cancer patients. Eur J Cancer. 2001;37:1006–1013.
   PubMed Web of Science ®Google Scholar
• Ravaioli A, Marangolo M, Pasquini E, et al. Bolus fluorouracil and leucovorin with oxaliplatin as first-line treatment in metastatic colorectal cancer. J Clin Oncol. 2002;20:2545–2550.
   PubMed Web of Science ®Google Scholar
• Levi F, Zidani R, Brienza S, et al. A multicenter evaluation of intensified, ambulatory, chronomodulated chemotherapy with oxaliplatin, 5-fluorouracil and leucovorin as initial treatment of patients with metastatic colorectal carcinoma. International Organization for Cancer Chronotherapy. Cancer. 1999;85:2532–2540.
   PubMed Web of Science ®Google Scholar
• Bertheault-Cvitkovic F, Jami A, Ithzaki M, et al. Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer. J Clin Oncol. 1996;14:2950–2958.
   PubMed Web of Science ®Google Scholar
• Maiello E, Gebbia V, Guiliani F, et al. 5-Fluorouracil and folinic acid with or without CPT-11 in advanced colorectal cancer patients: a multicenter randomized phase II study of the Southern Italy Oncology Group. Ann Oncol. 2000;11:1045–1051.
   PubMed Web of Science ®Google Scholar
• Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as fist-line treatment for metastatic colorectal cancer: a multicenter randomized trial. Lancet. 2000;355:1041–1047.
   PubMed Web of Science ®Google Scholar
• Saltz B, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000;343:905–914.
   PubMed Web of Science ®Google Scholar
• De Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938–2947.
   PubMed Web of Science ®Google Scholar
• Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22:23–30.
   PubMed Web of Science ®Google Scholar
• Aranda E, Diaz-Rubio E, Cervantes A, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with weekly high-dose 48-hour continuous-infusion fluorouracil for advanced colorectal cancer: a Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD) study. Ann Oncol. 1998;9:727–731.
   PubMed Web of Science ®Google Scholar
• De Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol. 1997;15:808–815.
   PubMed Web of Science ®Google Scholar
• Falcone A, Masi G, Allegrini G, et al. Biweekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil, and leucovorin: a pilot study in patients with metastatic colorectal cancer. J Clin Oncol. 2002;20:4006–4014.
   PubMed Web of Science ®Google Scholar
• Masi G, Allegrini G, Cupini S, et al. First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): results of a phase II study with a simplified biweekly schedule. Ann Oncol. 2004;15:1766–1772.
   PubMed Web of Science ®Google Scholar
• Souglakos J, Androulakis N, Syrigos K, et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a mutlicentre randomized phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer. 2006;94:798–805.
   PubMed Web of Science ®Google Scholar
• Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007;25:1670–1676.
   PubMed Web of Science ®Google Scholar
• Petrelli F, Borgonovo K, Cabiddu M, et al. FOLFIRI-bevacizumab as first-line chemotherapy in 3500 patients with advanced colorectal cancer: a pooled analysis of 29 published trials. Clin Colorectal Cancer. 2013;12:145–151.
   PubMed Web of Science ®Google Scholar
• Bendell JC, Bekaii-Saab TS, Cohn AL, et al. Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study. Oncologist. 2012;17:1486–1495.
   PubMed Web of Science ®Google Scholar
• Kozloff M, Ulcickas M, Berlin J, et al. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRITE observational cohort study. Oncologist. 2009;14:862–870.
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Rivera F, Berry S, et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol. 2009;20:1842–1847.
   PubMed Web of Science ®Google Scholar
• Stein A, Glockzin G, Wienke A, et al. Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature. BMC Cancer. 2012;12:356.
   PubMed Web of Science ®Google Scholar
• Morkel M, Riemer P, Blaker H, et al. Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance. Oncotarget. 2015;6:20785–20800.
   PubMedGoogle Scholar
• Therkildsen C, Bergmann TK, Hennrichsen-Schnack T, et al. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: a systematic review and meta-analysis. Acta Oncol. 2014;53:852–864.
   PubMed Web of Science ®Google Scholar
• Valtorta E, Misale S, Sartore-Bianchi A, et al. KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy. Int J Cancer. 2013;133:1259–1265.
   PubMed Web of Science ®Google Scholar
• Wong NA, Gonzalez D, Salto-Tellez M, et al. RAS testing of colorectal carcinoma: a guidance document from the association of clinical pathologists molecular pathology and diagnostics group. J Clin Pathol. 2014;67:751–757.
   PubMed Web of Science ®Google Scholar
• Ince WL, Jubb AM, Holden SN, et al. Association of k-ras, b-raf and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst. 2005;97:981–989.
   PubMed Web of Science ®Google Scholar
• Hurwitz HI, Yi J, Ince W, et al. The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of becacizumab with chemotherapy in previously untreated metastatic colorectal cancer. Oncologist. 2009;14:22–28.
   PubMed Web of Science ®Google Scholar
• Loupakis F, Cremolini C, Lonardi S, et al. Subgroup analyses in RAS mutant, BRAF mutant and all-wt mCRC pts treated with FOLFOXIRI plus bevacizumab (bev) or FOLFIRI plus bev in the TRIBE study. J Clin Oncol. 2014;32:abstr 3519.
   Google Scholar
• Moscetti L, Nelli F, Fabbri MA, et al. Maintenance single-agent bevacizumab or observation after first-line chemotherapy in patients with metastatic colorectal cancer: a multicenter retrospective study. Invest New Drugs. 2013;31:1035–1043.
   PubMed Web of Science ®Google Scholar